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Abstract: Stunting can afflict up to one-third of children in resource-constrained countries.
We hypothesized that low-grade systemic inflammation (defined as elevations in serum C-reactive
protein or alpha-1-acid glycoprotein) in infancy suppresses the growth hormone–insulin-like growth
factor (IGF) axis and is associated with subsequent stunting. Blood samples of 590 children from
periurban Dar es Salaam, Tanzania, were obtained at 6 weeks and 6 months of age as part of a
randomized controlled trial. Primary outcomes were stunting, underweight, and wasting (defined
as length-for-age, weight-for-age and weight-for-length z-scores < −2) between randomization and
endline (18 months after randomization). Cox proportional hazards models were constructed to
estimate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) of time to first stunting,
underweight, and wasting as outcomes, with measures of systemic inflammation, insulin-like growth
factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) as exposures, adjusting for
numerous demographic and clinical variables. The incidences of subsequent stunting, underweight,
and wasting were 26%, 20%, and 18%, respectively. In multivariate analyses, systemic inflammation
at 6 weeks of age was significantly associated with stunting (HR: 2.14, 95% CI: 1.23, 3.72; p = 0.002).
Children with higher levels of IGF-1 at 6 weeks were less likely to become stunted (HR: 0.58, 95% CI:
0.37, 0.93; p for trend = 0.019); a similar trend was noted in children with higher levels of IGF-1 at
6 months of age (HR: 0.50, 95% CI: 0.22, 1.12; p for trend = 0.07). Systemic inflammation occurs as
early as 6 weeks of age and is associated with the risk of future stunting among Tanzanian children.
Keywords: biomarkers; stunting; inflammation; growth; Tanzania; children
1. Introduction
Globally it is estimated that 156 million children under the age of 5 years were stunted in
2015 [1]. Stunting is associated with increased risk of diarrhea, pneumonia, reduced neurocognitive
Nutrients 2018, 10, 1158; doi:10.3390/nu10091158 www.mdpi.com/journal/nutrients
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capability, and diminished immunocompetence and accounts for about 1.2 million deaths annually
in children under 5 years of age [2,3]. Furthermore, stunting is associated with oral vaccine failure;
seroconversion rates for polio vaccination have been reported to be substantially lower among stunted
versus nonstunted children [4]. In resource—constrained settings, dramatic linear growth faltering
often occurs during the first 24 months of life [5]. This suggests that ameliorating growth faltering
early in infancy may be particularly advantageous in reducing mortality, improving future cognition,
and improving vaccine response [2–4].
Clinical studies in children with chronic inflammation, including inflammatory bowel disease and
chronic kidney disease, have shown that increased concentrations of inflammatory biomarkers and
reciprocally decreased concentrations of anabolic growth factors such as insulin-like growth factor-1
(IGF-1) are associated with linear growth faltering [6–9]. In resource-constrained settings, studies
have shown that recurrent enteric and/or respiratory infections are associated with reduced growth
velocity and stunting in children [10–12]. Recent data from Brazil and Zimbabwe have identified
relationships between infection, inflammation (as measured by high-sensitivity C-reactive protein
(hsCRP), and growth hormone (GH) resistance, whereas increased levels of GH, IGF-1, and IGF binding
protein-3 (IGFBP-3) were associated with growth indices independent of hsCRP [13,14]. Investigators
from Bangladesh and Brazil have also reported that enteric inflammation, measured by elevated
fecal myeloperoxidase or alpha-1-antitrypsin, was associated with subsequent decreases in linear
growth [15,16]. However, with the exception of the Bangladesh site, the remaining studies above were
limited in their ability to assess causal relationships given their case-control design.
The present study was designed to prospectively assess the contribution of inflammation and
anabolic growth markers during early infancy to subsequent early childhood stunting. We aimed to
determine the prospective association of inflammatory (alpha-1-acid glycoprotein (AGP), C-reactive
protein (CRP)) and growth (insulin-like growth factor 1 (IGF-1) and principal binding protein of
circulating IGF-1 concentration (IGFBP3)) biomarkers with stunting, wasting, and underweight
outcomes in a prospective cohort of young Tanzanian children at risk for growth faltering.
2. Materials and Methods
2.1. Study Design and Participants
Subjects were part of a randomized, double-blind, placebo-controlled trial designed to investigate
whether daily administration of zinc and/or multivitamins (vitamin C, vitamin E, thiamin, riboflavin,
niacin, vitamin B6, folate, and vitamin B12) to Tanzanian children would reduce the risk of infectious
morbidity and improve growth compared with placebo. Results of this trial have been published
previously [17]. Briefly, HIV-uninfected mothers of potentially eligible children were recruited into
the study and their infants were randomized to 1 of the 4 study arms between 5 and 7 weeks of
age. Children of multiple births and those with congenital anomalies or other conditions that would
interfere with the study procedures were excluded from the trial. Subjects were followed for 18 months.
Birth characteristics were obtained immediately after delivery whenever possible. At the time of
randomization, a study physician performed a clinical examination and drew a blood sample, and
a study nurse performed a history of morbidity and infant feeding practices and anthropometric
measurements. Mothers were asked to return to the study clinic with their children every 4 weeks
for data collection and standard clinical care, including growth monitoring, immunizations, routine
medical treatment for illnesses, and periodic vitamin A supplementation (100,000 IU at 9 months
and 200,000 IU at 15 months). At these visits, study nurses performed a morbidity history based
on maternal recall aided by the mother’s symptom diary that she received at the previous visit.
The symptom diary was a pictorial aid of illness symptoms (e.g., diarrhea, vomiting) where mothers
were asked to check off which days their child had experienced these symptoms. The study nurses
also measured the children’s weight using a digital infant balance with 10 g precision (Tanita) and
their length with 1 mm precision using a rigid length board with a movable foot piece. Length-for-age
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z-scores (LAZ), weight-for-length z-scores (WLZ), and weight-for-age z-scores (WAZ) were calculated
by using World Health Organization (WHO) child growth standards [18]. Stunting, wasting, and
underweight were defined as a LAZ, WLZ, and WAZ of 2 or more standard deviations (SDs) below
the WHO population median, respectively.
For the current post hoc analysis, a subset of children were chosen if they: (1) had blood samples
available at 6 weeks and 6 months of age, and (2) were not stunted (LAZ ≥ −2) at 6 weeks of age
(Figure 1).
Figure 1. Flowchart demonstrating the selection criteria for our patient population.
2.2. Biological Specimen Collection and Plasma Biomarker Measurement
Blood samples were obtained from children at baseline, 6 weeks, and 6 months of age.
Samples were centrifuged and plasma removed within 2 h of blood collection; aliquots were stored
in –80 ◦C freezers until shipped on dry ice for analysis. Serum samples were tested for biomarkers of
growth (IGF-1, IGFBP3) and systemic inflammation (AGP, CRP). IGF-1, IGFBP-3, CRP, and AGP were
measured by an ELISA method from R&D Systems (Minneapolis, MN, USA).
Nutrients 2018, 10, 1158 4 of 14
2.3. Statistical Analyses
Data were double entered using Microsoft Access software (Microsoft Corporation, Redmond,
WA, USA) and then converted to SAS datasets and uploaded to a secured Unix-based server for
analysis. Descriptive statistics were used to summarize baseline characteristics of the study population.
FrequDencies were reported for categorical variables and the mean ± standard deviation (SD)
for continuous variables. The concentrations of IGF-1 and IGF-BP3 at 6 weeks and 6 months of
age were categorized into quartiles and then used to examine their association with child growth.
CRP concentrations increase quickly in response to acute insult, peaking at approximately 48 h and
decreasing within a week, with a half-life of 19 h [19]. In contrast, AGP concentrations increased
more slowly and remained elevated for a longer period of time [20]. Taken together, CRP and
AGP measurements can be used to classify individuals who have inflammation from incubation
to early convalescence and into late convalescence [21]. Therefore, we explored the association
of inflammation with growth by defining systemic inflammation as a composite variable of either
CRP > 5 mg/L [22] or AGP > 1 g/L [23] and also by categorizing each CRP and AGP individually as
follows: CRP > 5 mg/L [22] or AGP > 1 g/L [23].
Cox proportional hazard models were constructed to estimate hazard ratios (HRs) and
corresponding 95% confidence intervals (CIs) for time to stunting, wasting, and underweight across
the quartile category of each biomarker and the presence of any inflammation. p-value for trend was
calculated by including the median value within each quartile as a continuous term in the regression
model. Each growth outcome was modeled separately, and the first time the child reached a score
of <−2 SD signified an “event.” Children who did not develop an “event” were censored from the
study at the time of last anthropometric assessment. In multivariate analysis, we further adjusted
for potential confounders including child sex, preterm birth, maternal age, maternal mid-upper arm
circumference (MUAC), maternal education, number of household assets (from a list that included
sofa, television, radio, refrigerator, and fan), treatment arm of parent trial, anthropometric z-score
at baseline, diarrhea, malaria, unscheduled clinical visits, or hospitalization. These covariates were
selected based on a p value < 0.10 in univariate analysis or traditionally considered as a risk factor for
child growth outcomes in the literature or biological pathway plausibility. We adjusted for morbidity
variables (e.g., diarrhea, malaria, unscheduled clinical visits, hospitalization) in the analysis because
we were aware of the possibility that the relationship between inflammation and poor growth may
be confounded by the high prevalence of infectious morbidities, which we previously reported in
our cohort [24]. Missing data were retained with use of the missing indicator method [25]. p-values
were 2-sided, with p < 0.05 considered statistically significant. All analyses were performed using SAS
version 9.4 (SAS Institute, Cary, NC, USA).
2.4. Ethics Statement and Study Data
Institutional approval was granted by the Harvard T.H. Chan School of Public Health Human
Subjects Committee (HSPH IRB 12875-129), the Muhimbili University of Health and Allied Science
Committee of Senate Research and Publications, the National Institute of Medical Research of
Tanzania, and the Tanzania Food and Drug Authority, and the parent trial was registered at
clinicaltrials.gov as NCT00421668. All mothers provided written informed consent for the parent trial
and subsequent analyses.
3. Results
Of the 2400 children who were enrolled in the parent trial for multivitamin and/or zinc
supplementation between August 2007 and December 2009, 590 met the eligibility criteria and were
included in the current substudy. Table 1 summarizes the baseline characteristics of the mothers and
children in our cohort. Average maternal age was 26 years, and almost 75% of mothers had one to
seven years of formal education. One-third had only one prior pregnancy, and the majority were
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married or cohabitating with a partner. About 50% of all infants were female, and 3% were born with
low birth weight. Mean± SD LAZ, WLZ, and WAZ scores at 6 weeks and 6 months of age are reported
in Table 1.
Table 1. Baseline maternal and child characteristics, n = 590.
Maternal Characteristics Mean± SD or n (%)
Age, years 26.4 ± 5.0
Formal education, years
0 11 (1.9)
1–7 434 (73.9)
≥8 142 (24.2)
Employment
Housewife without income 359 (61.6)
Housewife with income 183 (31.4)
Other 41 (7.0)
Married or cohabitating with partner 526 (89.9)
Prior pregnancies
None 196 (33.4)
1–4 380 (64.7)
≥5 11 (1.9)
Mid-upper arm circumference (cm) 26.8 ± 3.1
Household Socioeconomic Characteristics
Daily food expenditure per person in household <1000 Tanzanian shillings 1 144 (26.0)
Household possessions, 2 n
0 178 (30.4)
1–3 339 (57.9)
≥3 69 (11.8)
Child Baseline Characteristics
Male 283 (48.0)
Low birth weight < 2500 g 16 (2.7)
Born preterm < 37 weeks 59 (10.8)
Apgar score ≤ 7 at 5 min after birth 8 (1.5)
Anthropometrics at 6 Weeks
Length-for-age z-score −0.14 ± 1.02
Weight-for-length z-score −0.05 ± 1.18
Weight-for-age z-score −0.20 ± 0.87
Anthropometrics at 6 Months
Length-for-age z-score −0.38 ± 1.13
Weight-for-length z-score 0.08 ± 1.17
Weight-for-age z-score −0.24 ± 1.06
Note: 1 Approximately USD 0.80 at the time of the study. 2 From a list that included sofa, television, radio,
refrigerator, and fan. SD, standard deviation.
The incidences of stunting, underweight, and wasting during the follow-up period were 26%,
20%, and 18%, respectively. We previously reported [24] data regarding infectious morbidities in our
cohort. For the purpose of this analysis, 1.4% and 1.2% of children had hospitalizations reported
and 18.3% and 14.6% had unscheduled outpatient visits reported after 6 weeks and after 6 months,
respectively, until the end of study follow-up.
All biomarker concentrations had skewed distributions, therefore we report mean ± SE
concentrations over the follow-up period. Levels of CRP, AGP, and IGF-BP3 increased significantly
and serum concentrations of IGF-1 decreased significantly during the follow-up period, as shown in
Figure 2.
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Figure 2. Levels of inflammatory (C-reactive protein (CRP), alpha-1-acid glycoprotein (AGP)) and
growth (insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3))
biomarkers at 6 weeks and 6 months in Tanzanian children who did or did not develop subsequent
stunting. Please note: In this figure “stunted” is defined as children who developed stunting during
the follow-up period.
Levels of CRP and AGP increased significantly, with mean ± SE (Standard Error) concentrations
at 6 weeks and 6 months, respectively, as follows: CRP: 0.99 ± 0.15 mg/L, 3.02 ± 0.33 mg/L, p < 0.001;
AGP: 0.39± 0.01 g/L, 0.74± 0.01 g/L, p < 0.001. Serum concentrations of IGF-1 significantly (p < 0.001)
decreased over time: mean± SE concentration was 39.92± 0.49 ng/mL at 6 weeks, 24.78± 0.42 ng/mL
at 6 months. Likewise, mean ± SE IGFBP3 significantly (p < 0.001) increased from 976.4 ± 13.5 ng/mL
at 6 weeks to 1000.37 ± 13.11 ng/mL at 6 months. p1, comparing biomarker between stunted status
(yes/no) at 6 weeks; p2, comparing biomarker between stunted status (yes/no) at 6 months; p3,
comparing biomarker beween 6 weeks and 6 months.
Table 2 summarizes the Spearman’s correlation coefficients relating biomarkers of growth
metabolism with inflammation. Our findings were notable for a strong negative association of
CRP with IGF-1 at 6 weeks and at 6 months. AGP had a strong negative association with IGF-1
but only at 6 months. AGP and CRP were strongly and positively associated with each other at
both time points. Six-week levels of AGP, IGF-1, and IGFBP3 were positively correlated with their
6 month concentrations.
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Table 2. Correlation coefficient matrix of inflammatory and growth biomarkers.
Biomarkers rs
At 6 Weeks At 6 Months
AGP, g/L CRP,mg/L
IGF-1,
ng/mL
IGFBP3,
ng/mL
AGP,
mg/dL
CRP,
mg/L
IGF-1,
ng/mL
IGFBP3,
ng/mL
At 6 weeks
AGP, g/L − +0.36 ** −0.16 +0.05 +0.25 ** +0.02 −0.02 −0.01
CRP, mg/L − −0.19 ** −0.05 +0.03 −0.02 −0.01 −0.01
IGF-1, ng/mL – +0.49 ** +0.01 −0.02 +0.24 ** +0.16 **
IGFBP3, ng/mL − +0.05 +0.00 +0.07 +0.48 **
At 6 months
AGP, g/L − +0.44 ** −0.32 ** −0.09
CRP, mg/L − −0.20 ** −0.12
IGF-1, ng/mL − +0.42 **
IGFBP3, ng/mL −
Note: Values are Spearman’s rank-order correlation coefficient (rs). ** p < 0.0001. AGP, alpha-1-acid glycoprotein;
CRP, C-reactive protein; IGF1, insulin-like growth factor-1; IGFBP3, insulin-like growth factor binding protein-3.
In multivariate analyses (Table 3), children with evidence of systemic inflammation (CRP > 5 mg/L
or AGP > 1 g/L) at 6 weeks were 2.14 times (95% CI: 1.23, 3.72; p = 0.002) more likely to become
stunted over the course of follow-up than children without these elevated markers of inflammation
(both CRP ≤ 5 mg/L and AGP ≤ 1 g/L). Systemic inflammation was also significantly associated
with stunting at 6 months of age (Table 4) in the univariate analysis with 1.78 times (95% CI: 1.16, 2.72;
p = 0.01) increased risk of stunting, but there was no statistically significant relationship in multivariate
models (HR 1.14; 95% CI 0.68, 1.93; p = 0.62). Children with serum IGF-1 in the highest quartile at
6 weeks and 6 months of age had a 42% (HR 0.58, 95% CI 0.37, 0.93; p for trend = 0.019) and 45%
(HR 0.55, 95% CI 0.22, 1.12; p for trend = 0.07) reduced risk of becoming stunted than children with
concentrations in the lowest quartile.
Similarly, in adjusted analyses with underweight as the primary outcome, children with systemic
inflammation (CRP > 5 mg/L or AGP > 1 g/L) at 6 weeks showed a trend toward increased risk of
underweight (HR: 1.65; 95% CI: 0.80, 3.39; p = 0.058) as compared with children without inflammation.
In multivariate models, children with IGF-1 in the highest quartile at 6 weeks had 45% (HR 0.55,
95% CI: 0.31, 0.98; p for trend = 0.052) reduced risk of becoming underweight than children with
concentrations in the lowest quartile. This association was also noted in the 6 month univariate models
(HR 0.27, 95% CI: 0.13, 0.55; p for trend = 0.002), but this relationship was no longer significant in
the multivariable model. Children with IGFBP3 in the highest quartile at 6 months only had 77%
(HR 0.23, 95% CI: 0.08, 0.63; p for trend = 0.01) reduced risk of becoming underweight than children
with concentrations in the lowest quartile in the adjusted model.
We found no significant relationship between any 6 week biomarker with wasting in unadjusted or
adjusted models. In the 6 month unadjusted model, children with IGFBP3 levels in the highest quartile
had a 58% (HR = 0.42; 95% CI: 0.18, 0.97; p for trend = 0.04) lower risk of becoming wasted compared
to children with concentrations in the lowest quartile, and this relationship remained significant in
the multivariable model (HR = 0.33; 95% CI: 0.11, 1.00; p for trend = 0.049). The other biomarkers
(CRP, AGP, and IGF-1) were not significantly related to the risk of wasting in 6 month unadjusted
and adjusted hazard models. Lastly, as shown in Table 5, in models studying the association of each
variable CRP > 5 mg/L and AGP > 1 g/L separately at 6 weeks and 6 months of age with subsequent
stunting, wasting, and underweight, only AGP > 1 at 6 weeks was found to be significantly associated
with stunting (HR 3.20, 95% CI: 1.38, 7.40, p for trend = 0.01).
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Table 3. Association of inflammatory (CRP, AGP) and growth (IGF-1, IGFBP-3) biomarkers at 6 weeks with subsequent stunting, wasting, and underweight.
Stunting Underweight Wasting
Events/n Univariate HR(95% CI) p
1 Multivariate 2
HR (95% CI) p
1 Events/n Univariate HR(95% CI) p
1 Multivariate 2
HR (95% CI) p
1 Events/n Univariate HR(95% CI) p
1 Multivariate 2
HR (95% CI) p
1
CRP > 5mg/L/AGP > 1g/L
No 139/542 1.00
0.01
1.00
0.002
95/532 1.00
0.10
1.00
0.058
74/506 1.00
0.20
1.00
0.14Yes 15/32 1.96 (1.15–3.33) 2.14 (1.23–3.72) 9/31 1.76 (0.89–3.50) 1.65 (0.80–3.39) 7/30 1.66 (0.77–3.61) 1.74 (0.78–3.90)
Insulin-like Growth Factor-1, ng/mL
Q1 51/145 1.00
0.006
1.00
0.019
33/136 1.00
0.057
1.00
0.052
23/125 1.00
0.13
1.00
0.15
Q2 38/143 0.66 (0.43–1.00) 0.67 (0.43–1.04) 25/144 0.67 (0.40–1.12) 0.67 (0.39–1.14) 20/132 0.77 (0.42–1.40) 0.79 (0.42–1.46)
Q3 36/146 0.66 (0.42–1.01) 0.63 (0.41–0.99) 25/145 0.71 (0.43–1.20) 0.72 (0.42–1.23) 22/141 0.82 (0.46–1.48) 0.86 (0.47–1.58)
Q4 30/145 0.53 (0.34–0.83) 0.58 (0.37–0.93) 21/143 0.57 (0.33–0.99) 0.55 (0.31–0.98) 16/143 0.59 (0.31–1.11) 0.59 (0.30–1.15)
Insulin-like Growth Factor Binding Protein-3, ng/mL
Q1 39/147 1.00
0.94
1.00
0.26
30/144 1.00
0.27
1.00
0.33
23/130 1.00
0.38
1.00
0.57
Q2 42/147 1.05 (0.68–1.62) 0.91 (0.57–1.43) 29/141 0.99 (0.59–1.65) 0.95 (0.56–1.61) 20/136 0.81 (0.45–1.48) 0.83 (0.44–1.54)
Q3 33/145 0.83 (0.52–1.31) 0.83 (0.51–1.35) 23/143 0.80 (0.47–1.39) 0.79 (0.45–1.40) 19/142 0.75 (0.41–1.39) 0.84 (0.45–1.58)
Q4 41/145 1.08 (0.70–1.68) 1.17 (0.74–1.85) 22/145 0.76 (0.44–1.32) 0.79 (0.45–1.39) 19/138 0.78 (0.43–1.44) 0.84 (0.45–1.56)
Note: 1 p-values for trend for quartile variables were calculated using median value in each quartile category. 2 Models adjusted for child sex, preterm birth, maternal age, maternal MUAC,
maternal education, number of household assets, treatment arm, z-score at 6 months, diarrhea, malaria, unscheduled clinical visits, and hospitalization. AGP, alpha-1-acid glycoprotein;
CRP, C-reactive protein, IGF1, insulin-like growth factor-1; IGFBP3, insulin-like growth factor binding protein-3; MUAC, mid-upper arm circumference.
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Table 4. Association of inflammatory (CRP, AGP) and growth (IGF-1, IGFBP-3) biomarkers at 6 months with subsequent stunting, wasting, and underweight.
Stunting Underweight Wasting
Events/n Univariate HR(95% CI) p
1 Multivariate 2
HR (95% CI) p
1 Events/n Univariate HR(95% CI) p
1 Multivariate 2
HR (95% CI) p
1 Events/n Univariate HR(95% CI) p
1 Multivariate 2
HR (95% CI) p
1
CRP > 5 mg/L/AGP > 1 g/L
No 57/374 1.00
0.01
1.000
0.62
57/398 1.00
0.76
1.00
0.66
39/381 1.00
0.86
1.00
0.62Yes 34/138 1.78 (1.16–2.72) 1.14 (0.68–1.93) 19/141 0.92 (0.55–1.55) 1.15 (0.62–2.13) 15/144 1.06 (0.58–1.91) 1.21 (0.57–2.54)
Insulin-like Growth Factor-1, ng/mL
Q1 32/123 1.00
0.0001
1.00
0.07
30/128 1.00
0.002
1.00
0.09
18/127 1.00
0.11
1.00
0.97
Q2 26/127 0.74 (0.44–1.24) 1.15 (0.62–2.16) 20/134 0.61 (0.34–1.07) 0.72 (0.37–1.42) 10/130 0.51 (0.24–1.10) 0.17 (0.05–0.64)
Q3 22/132 0.59 (0.34–1.01) 0.89 (0.47–1.68) 16/139 0.46 (0.25–0.84) 0.53 (0.26–1.08) 17/134 0.85 (0.44–1.65) 1.35 (0.61–3.01)
Q4 11/132 0.28 (0.12–0.56) 0.50 (0.22–1.12) 10/140 0.27 (0.13–0.55) 0.56 (0.26–1.21) 9/136 0.43 (0.20–0.97) 0.63 (0.23–1.71)
Insulin-like Growth Factor Binding Protein-3, ng/mL
Q1 26/125 1.00
0.34
1.00
0.45
26/133 1.00
0.009
1.00
0.01
18/131 1.00
0.04
1.00
0.049
Q2 20/134 0.64 (0.36–1.14) 0.90 (0.45–1.80) 21/140 0.73 (0.41–1.30) 0.60 (0.32–1.17) 15/131 0.77 (0.39–1.53) 0.96 (0.40–2.28)
Q3 27/127 0.99 (0.58–1.70) 1.49 (0.77–2.87) 21/133 0.82 (0.46–1.45) 0.92 (0.48–1.76) 13/135 0.70 (0.34–1.43) 0.75 (0.30–1.91)
Q4 19/129 0.66 (0.36–1.19) 1.14 (0.55–2.37) 9/136 0.34 (0.16–0.72) 0.23 (0.08–0.63) 8/131 0.42 (0.18–0.97) 0.33 (0.11–1.00)
Note: 1 p-values for trend for quartile variables were calculated using median value in each quartile category. 2 Models adjusted for child sex, preterm birth, maternal age, maternal MUAC,
maternal education, number of household assets, treatment arm, z-score at 6 months, diarrhea, malaria, unscheduled clinical visits, and hospitalization. AGP, alpha-1-acid glycoprotein;
CRP, C-reactive protein; IGF1, insulin-like growth factor-1; IGFBP3, insulin-like growth factor binding protein-3; MUAC, mid-upper arm circumference.
Nutrients 2018, 10, 1158 10 of 14
Table 5. Association of CRP and AGP biomarkers at 6 weeks and 6 months with subsequent stunting, wasting, and underweight.
Stunting Underweight Wasting
Events/n UnivariateHR (95% CI) p
Multivariate 1
HR (95% CI)
p Events/n UnivariateHR (95% CI) p
Multivariate 1
HR (95% CI)
p Events/n UnivariateHR (95% CI) p
Multivariate 1
HR (95% CI)
p
6 weeks
CRP > 5 mg/L
No 135/524 1.00
0.06
1.00
0.07
94/513 1.00
0.54
1.00
0.57
72/488 1.00
0.55
1.00
0.64Yes 10/22 1.85(0.97–3.52) 1.86(0.96–3.58) 5/22 1.33(0.54–3.27) 1.30(0.52–3.24) 4/21 1.39(0.51–3.81) 1.37(0.49–3.81)
AGP > 1 g/L
No 145/555 1.00
0.13
1.00
0.01
99/545 1.00
0.19
1.00
0.055
78/518 1.00
0.45
1.00
0.27Yes 6/14 1.89(0.84–4.29) 3.20(1.38–7.40) 4/13 1.95(0.72–5.30) 2.75(0.98–7.71) 3/13 1.56(0.49–4.93) 1.97(0.60–6.52)
6 months
CRP > 5 mg/L
No 76/414 1.00
0.97
1.00
0.55
67/436 1.00
0.19
1.00
0.53
46/424 1.00
0.93
1.00
0.81Yes 14/72 1.07(0.61–1.90) 0.82(0.42–1.60) 7/73 0.60(0.27–1.30) 0.76(0.34–1.74) 7/75 0.97(0.46–2.05) 0.89(0.34–2.33)
AGP > 1 g/L
No 62/400 1.00 0.01 1.00 0.76 60/424 1.00 0.98 1.00 0.85 40/408 1.00 0.46 1.00 0.31
Yes 26/103 1.82(1.15–2.87) 0.92(0.51–1.63) 15/105 0.99(0.56–1.75) 1.07(0.54–2.13) 13/109 1.27(0.68–2.37) 1.50(0.68–3.31)
Note: 1 Adjusted for child sex, preterm birth, maternal age, maternal education, maternal MUAC, number of household assets, treatment arm, baseline z-score, and morbidity
(hospitalization or unscheduled clinical visits). AGP, alpha-1-acid glycoprotein; CRP, C-reactive protein.
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4. Discussion
In this large prospective cohort study using data collected from age six weeks for 18 months,
we found that systemic inflammation (CRP > 5 mg/L or AGP > 1 g/L) at 6 weeks of age was
significantly associated with increased risk of subsequent stunting. Children with higher levels of
IGF-1 at 6 weeks and 6 months were substantially less likely to become stunted or underweight. Finally,
our findings were notable for a strong negative association between CRP and IGF-1 at both 6 weeks
and 6 months, with 6 week AGP levels strongly and positively associated with subsequent AGP levels
at 6 months.
Prior studies reported mixed associations between inflammation and growth factors with
subsequent growth faltering. Prendergast et al. [14] performed a case control study of 202 Zimbabwean
children and measured biomarkers of inflammation (CRP, AGP, IL-6) and growth hormone-IGF axis
(IGF-1, IGFBP3) in infant plasma at 6 weeks and 3, 6, 12, and 18 months. They showed that from
6 weeks to 12 months of age, levels of CRP and AGP were consistently higher and of IGF-1 and IGFBP3
were lower in cases (defined as children with HAZ < −2 at 18 months) versus controls (defined as
children with HAZ > −0.5 at 18 months). IGF-1 correlated inversely with inflammatory markers at all
time points. In multivariate analysis, higher log10 levels of CRP (adjusted OR 3.06 (95% CI 1.34, 6.99);
p = 0.008) during infancy were significantly associated with stunting. Similarly, we also noted a strong
negative correlation of CRP with IGF-1 and showed that early inflammation at 6 weeks as measured
by both AGP and CRP was associated with an increased risk of stunting. Our results confirm and
extend the Zimbabwean data in several ways. First, we studied a combined inflammation variable of
CRP > 5 mg/L and AGP > 1 g/dL, which allowed us to capture infants with evidence of biochemical
evidence of either acute or chronic inflammation. Second, our prospective study design allowed us to
better illustrate the risk of subsequent growth faltering versus the Zimbabwean nested case-control
study. Finally, we collected monthly repeated anthropometric data versus the 3 month measures
in Zimbabwe.
Our results are consistent with the hypothesis that inflammation suppresses the growth
hormone–IGF axis and demonstrate that children with higher levels of IGF-1 in the first year of life are
less likely to become stunted or underweight. This is supported by data from a study in Brazil [13] in
which, after adjusting for inflammation (as measured by hsCRP), IGF-1 and IGFBP-3 were positively
and significantly associated with height-for-age, weight-for-age, and weight-for-height z-scores.
The authors also reported a similar negative association of hsCRP with IGF-1 and IGFBP-3. However,
contrary to our findings, this study did not find a relationship between hsCRP and anthropometric
measures. This study was limited by the use of cross-sectional measures of height compared to our
design, in which successive assessments of growth over time were made. Furthermore, they defined
malnutrition as children with WAZ scores < −2 and matched “non-malnourished controls” as having
WAZ scores > −1, whereas our and others’ use of HAZ better reflects chronic malnutrition [26,27].
Arndt et al. reported associations between fecal markers of inflammation, namely neopterin
(NEO), myeloperoxidase (MPO), and alpha-1-antitrypsin (AAT), and short-term linear growth in a birth
cohort of 246 Bangladeshi children [15]. They reported that elevated MPO levels, but not NEO or AAT
levels, were associated with lower short-term linear growth during the second year of life. Their study,
however, did not report whether these changes were reflected in measures of systemic inflammation.
In a case-control study, Guerrant et al. measured biomarkers of both systemic (hsCRP, serum amyloid
A (SAA), soluble cluster of differentiation 14, lipopolysaccharide binding protein) and enteric (fecal
MPO, NEO) inflammation in children from several impoverished communities in Fortaleza, Brazil [16].
They reported that lower SAA levels correlated with stunting at enrollment, and that subsequent mean
HAZ scores were significantly lower in those with higher fecal MPO or A1AT (alpha-1 antitrypsin).
They also reported a significant correlation between impaired linear growth (delta HAZ) (r = −0.132,
p = 0.046, n = 231) and higher values of plasma SAA, but no significant correlations were noted with
hsCRP levels and HAZ or WAZ at study start or with delta HAZ. This study, however, enrolled
children who were older (14.3 ± 5.4 months) at baseline and had biomarkers measured within 1 month
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of enrollment with follow-up anthropometry at 2–6 months. In contrast, we enrolled children at
6 weeks of age and collected anthropometric data monthly over the 18-month period of follow-up.
Several strengths of our study merit mention. We followed a large cohort of initially well-nourished
children at risk for growth faltering. Our monthly repeated measures of length and weight allowed
our analysis to take into consideration that normal human growth is variable, with intervals of rapid
growth separated by periods of no measurable growth [28]. We measured serum biomarkers at two
time points in the first year of life, in early infancy (6 weeks of age) and at 6 months of age. Finally,
we included multiple potentially confounding factors in our multivariable models, including clinically
apparent infections. We were limited by the lack of maternal levels of growth/insulin metabolism
and inflammatory biomarkers. We were additionally limited by the consideration that several of the
micronutrients under study in the parent trial, such as zinc, are of crucial importance for immune
response (although treatment arm was considered in all multivariable models).
In summary, we demonstrated that systemic inflammation occurs in Tanzanian infants as early
as 6 weeks of age and that this inflammation is strongly associated with subsequent stunting in
childhood. In addition, children who had higher levels of IGF-1 at both 6 weeks and 6 months were
significantly less likely to become stunted. Our work extends the current literature by defining an
early critical period of life when both growth faltering and systemic inflammation occur. The finding
that serum measures of inflammation and anabolic growth are significant biomarkers in early infancy
for subsequent growth faltering brings up the possibility that subclinical infectious or inflammatory
processes, such as have been hypothesized to occur in environmental enteric dysfunction, mediate
growth failure in children. These findings provide support for continued focus and the need for
intervention as early as the first few months of life in children at risk for stunting who live in
resource-constrained regions of the world.
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